VSST, BPAX, ATRN, TRID – Today’s Watchlist

BioSante Pharmaceuticals, Inc. BPAX

You’ve heard us say, “if it ain’t broke, don’t fix it”. BPAX broke its resistance on Tuesday, hitting a HOD of .6749, closing the day at .66, and kicking off this short week in good fashion. So far, our total gains on BPAX are sitting at 74%

There are certain groups who believe wrongdoing was taking place with regard to the statements released by the company about its failed product, LibiGel. We are reserving judgement until more information comes to light, but thought you should be made aware of the situation as well. 

NEW YORK, Jan 11, 2012 (BUSINESS WIRE) — Levi & Korsinsky is investigating potential claims on behalf of purchasers of BioSante Pharmaceuticals, Inc. (“BioSante” or the “Company”) (Nasdaq: BPAX) securities concerning possible violations of federal securities laws.

For more information, click here: http://zlk.9nl.com/biosante-pharmaceuticals-bpax.

Atrinsic, Inc. ATRN

ATRN saw a modest 5% increase yesterday, on lighter-than-average volume. It is good to see a consolidation and sideways trading action on decreased volume; it appears as if ATRN is building a new base for its next leg up.

The RSI still appears oversold, and has plenty of room to climb higher from here

Trident Microsystems, Inc. TRID

TRID had its first down day Tuesday since we’ve been following this stock. After 125% in gains, a little pullback is to be expected, but we wont let the symbol slip from our radar just yet. The stock maintained a higher low of .127, only to close at .143, for a 13% intraday gain.

Voice Assist, Inc. VSST

This stock hit its 52-week low yesterday, so we are going to be watching closely for signs that its hit its bottom, that we might catch it on the rebound.

Just as recently as October, VSST was trading in the .70-.80 range, and between 1.25-1.50 back in August. Should the stock recover from this selloff and return to those previous prices, gains of 250%-600% could be in store.

This all may not happen overnight, thus we would categorize this as a long term play. As you’ve seen with our other bottom plays, its always best to begin paying attention early, so as not to miss a beat when the stock begins to turn up from its bottom.  

We think that this company has a great technology that could eventually take off, but don’t take our word for it: The company offers free 30-day trials here.